{
    "id": "dbpedia_7115_0",
    "rank": 46,
    "data": {
        "url": "https://www.linkedin.com/posts/arieldora_digital-health-community-in-berlin-and-beyond-activity-7066479396269760512-FztB",
        "read_more_link": "",
        "language": "en",
        "title": "Ariel Dora Stern posted on LinkedIn",
        "top_image": "https://media.licdn.com/dms/image/v2/D4E22AQE8CdEpHoqO1g/feedshare-shrink_800/feedshare-shrink_800/0/1684437324836?e=2147483647&v=beta&t=sS0jYqepIK0b1i_fKEPxzqmSl_vIkGC8xRRr5XuECNU",
        "meta_img": "https://media.licdn.com/dms/image/v2/D4E22AQE8CdEpHoqO1g/feedshare-shrink_800/feedshare-shrink_800/0/1684437324836?e=2147483647&v=beta&t=sS0jYqepIK0b1i_fKEPxzqmSl_vIkGC8xRRr5XuECNU",
        "images": [
            "https://media.licdn.com/dms/image/v2/D4D16AQH2PGigke8qnw/profile-displaybackgroundimage-shrink_200_800/profile-displaybackgroundimage-shrink_200_800/0/1712004335819?e=2147483647&v=beta&t=uia5VEzsYOMQqTE-kXdCuGForPMln3GXOp6Vm96X8Kc"
        ],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            ""
        ],
        "tags": null,
        "authors": [
            "Ariel Dora Stern"
        ],
        "publish_date": "2023-05-22T18:26:16.879000+00:00",
        "summary": "",
        "meta_description": "Ariel Dora Stern posted images on LinkedIn",
        "meta_lang": "en",
        "meta_favicon": "https://static.licdn.com/aero-v1/sc/h/al2o9zrvru7aqj8e1x2rzsrca",
        "meta_site_name": "",
        "canonical_link": "https://www.linkedin.com/posts/arieldora_digital-health-community-in-berlin-and-beyond-activity-7066479396269760512-FztB",
        "text": "Thank you #Nobel Prize Laureate Jean Tirole & Pierre Dubois for a thought-provoking Health Economics Conference at Toulouse School of Economics last week! Shout-out to Ariel Dora Stern for her enlightening keynote ğŸ¤ showing that there can be innovation in regulatory policy itself. In particular: 1ï¸âƒ£ \"BreakThrough Designation (BTD) launched by FDA in 2012 does not shorten regulatory approval periods BUTâ€¦ shortens clinical development time, in particular the length of late-stage trials, by ~5 months. 2 main comments about mechanism of action: âœ” It benefits more to â€œlow experienceâ€ firms âœ” Trial characteristics are less complex than average ğŸ‘‰ Interestingly, one can get to a similar conclusion by asking precisely the humans who made the regulatory judgment of interest! 2ï¸âƒ£ Digital Health: success of German #DiGA âœ” 50+ Apps today available (after 3 yrs of policy), covering various use cases (diagnosis, monitoring, support, â€¦), with same HTA & pricing mechanisms as for drugs. â‰ // & differences to FDA #PreCert program, which abruptly stopped in Sept 22 were discussed ğŸ¤ We also had a stimulating panel on the use of Health Data, Platforms & Digital Technologies for Innovation chaired by Jean Tirole, with Edwin Morley-Fletcher & Ariel Dora Stern ğŸ‘‰ I was happy to present Dassault SystÃ¨mes' ambition in #LifeSciences & #Healthcare, and how #VirtualTwin can accelerate therapeutic innovation and improve medical practice. Among examples shared, I mentioned #SCA (synthetic control arms), #MediTwin, our partnership with FDA for in silico clinical trials. ğŸŒ© Key challenges include: 1ï¸âƒ£ Access to data, which itself requires a solid business model, data standardization, trusted Cloud 2ï¸âƒ£ Reimbursement & adoption in physicians workflow -> change management will be key ğŸ™ Thanks a lot to all participants for exciting discussions!"
    }
}